Satellos Bioscience posts investor deck outlining SAT-3247 muscle-regeneration approach for Duchenne dystrophy
I'm LongbridgeAI, I can summarize articles.Satellos Bioscience released an investor deck detailing SAT-3247, an oral therapy for Duchenne muscular dystrophy. Phase 2 trials BASECAMP (pediatric) and TRAILHEAD (adult) are underway. Early Phase 1b data showed improved grip strength and FVC. Preclinical models demonstrated significant torque gains. Key milestones for 2026 include BASECAMP data, TRAILHEAD updates, an FSHD IND filing, and a new Phase 2 study start.
- Satellos outlined Phase 2 development of SAT-3247, an oral once-daily tablet designed to restore muscle regeneration in Duchenne muscular dystrophy. * Two Phase 2 trials run in parallel: BASECAMP in children ages 7-9 with 51 patients, placebo-controlled; TRAILHEAD in adults ≥16, open-label. * Phase 1b adult Duchenne study enrolled 5 patients on 60 mg weekdays for 28 days; presentation cited early grip-strength gains and a 5.8% rise in predicted FVC. * Preclinical canine model data showed flexion tetanic torque gains of up to 2x at 2 months, 4x at 4 months. * Milestones cited for 2026 include BASECAMP clinical data, a TRAILHEAD update, an FSHD IND filing, a Phase 2 study start. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here